Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Accured Expenses (2020 - 2025)

Apellis Pharmaceuticals has reported Change in Accured Expenses over the past 6 years, most recently at $25.4 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 56.24% year-over-year to $25.4 million; the TTM value through Dec 2025 reached $25.4 million, up 39.86%, while the annual FY2025 figure was $25.4 million, 39.86% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $25.4 million at Apellis Pharmaceuticals, up from $7.3 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $65.3 million in Q2 2021 and troughed at -$64.6 million in Q3 2021.
  • A 5-year average of $3.1 million and a median of $9.6 million in 2023 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: surged 15415.68% in 2021 and later tumbled 742.69% in 2023.
  • Year by year, Change in Accured Expenses stood at $31.7 million in 2021, then plummeted by 52.83% to $15.0 million in 2022, then fell by 20.74% to $11.9 million in 2023, then soared by 37.11% to $16.2 million in 2024, then skyrocketed by 56.24% to $25.4 million in 2025.
  • Business Quant data shows Change in Accured Expenses for APLS at $25.4 million in Q4 2025, $7.3 million in Q3 2025, and $22.9 million in Q2 2025.